US EditionNanobiotix doses first patient in Phase 2 study of radioenhancer in NSCLC - BioTuesdays
Summary by biotuesdays.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
All
Left
Center
Right
Nanobiotix doses first patient in Phase 2 study of radioenhancer in NSCLC - BioTuesdays
Nanobiotix (NASDAQ:NBTX; Euronext:NANO) has announced the dosing of the first patient in its CONVERGE Phase 2 study, evaluating its potential first-in-class radioenhancer, JNJ-1900 (NBTXR3), in patients with stage 3 non-small cell lung cancer (NSCLC). The company noted that the CONVERGE study is sponsored by Janssen, a Johnson & Johnson company, under a global licencing agreement. The study is a Phase 2 randomized controlled clinical trial. “We …
Coverage Details
Total News Sources2
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
